Marshall Wace, LLP Concert Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.34 - $5.84 $125,990 - $169,535	29,030 New	29,030 $169,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $6.36 $249,608 - $566,968	89,146 New	89,146 $374,000
Q1 2022 May 16, 2022	SELL	$2.73 - $3.94 $123,895 - $178,809	-45,383 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.69 - $4.22 $79,543 - $124,785	-29,570 Reduced 39.45%	45,383 $143,000
Q3 2021 Nov 15, 2021	BUY	$3.17 - $4.15 $172,758 - $226,166	54,498 Added 266.43%	74,953 $245,000

Q2 2021 Aug 13, 2021	SELL	$3.77 - $5.24 $121,492 - $168,864	-32,226 Reduced 61.17%	20,455 $86,000
Q1 2021 May 17, 2021	BUY	$4.86 - $13.07 $161,429 - $434,133	33,216 Added 170.64%	52,681 $263,000
Q4 2020 Feb 16, 2021	BUY	$9.48 - $12.84 $184,528 - $249,930	19,465 New	19,465 $246,000
Q4 2019 Feb 14, 2020	SELL	$5.71 - $9.22 $22,234 - $35,902	-3,894 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$5.88 - $12.35 $576,257 - $1.21 Million	-98,003 Reduced 96.18%	3,894 $23,000
Q2 2019 Aug 14, 2019	BUY	$9.44 - $13.12 $961,907 - $1.34 Million	101,897 New	101,897 $1.22 Million

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.